Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei F19 + fructo-oligosaccharides + galactooligosaccharides
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This synbiotic formulation consists of the probiotic strain *Lactobacillus paracasei* F19 combined with the prebiotic fibers fructo-oligosaccharides (FOS) and galactooligosaccharides (GOS). *L. paracasei* F19 is a lactic acid bacterium known for its ability to survive gastric transit and adhere to the intestinal mucosa, where it modulates the immune system and inhibits pathogens. The prebiotics FOS and GOS are non-digestible carbohydrates that selectively stimulate the growth and activity of beneficial bacteria, such as Bifidobacteria and Lactobacilli, in the colon. This combination is primarily investigated for its role in early-life immune development, prevention of allergic diseases such as atopic dermatitis (eczema), and maintenance of healthy gut microbiota in infants and children.
- Other names
- L. paracasei F19 + FOS + GOSsynbiotic combination (L. paracasei F19, FOS, GOS)
Beyond the preview
Go deeper on lactobacillus paracasei F19 + fructo-oligosaccharides + galactooligosaccharides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei F19 + fructo-oligosaccharides + galactooligosaccharides.